2023 ESC Guidelines for the management of cardiomyopathies: Developed by the task force on the management of cardiomyopathies of the European Society of …
• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …
off-label use of medication should be limited to situations where it is in the patient's interest …
2024 ESC guidelines for the management of chronic coronary syndromes: developed by the task force for the management of chronic coronary syndromes of the …
• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …
off-label use of medication should be limited to situations where it is in the patient's interest …
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic …
ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …
that, unless otherwise provided for by national regulations, offlabel use of medication should …
Cardiac sarcoidosis: phenotypes, diagnosis, treatment, and prognosis
J Lehtonen, V Uusitalo, P Pöyhönen… - European heart …, 2023 - academic.oup.com
Cardiac sarcoidosis (CS) results from epithelioid cell granulomas infiltrating the myocardium
and predisposing to conduction disturbances, ventricular tachyarrhythmias, and heart …
and predisposing to conduction disturbances, ventricular tachyarrhythmias, and heart …
The Lancet Commission to reduce the global burden of sudden cardiac death: a call for multidisciplinary action
E Marijon, K Narayanan, K Smith, S Barra, C Basso… - The Lancet, 2023 - thelancet.com
Despite major advancements in cardiovascular medicine, sudden cardiac death (SCD)
continues to be an enormous medical and societal challenge, claiming millions of lives …
continues to be an enormous medical and societal challenge, claiming millions of lives …
Excessive Trabeculation of the Left Ventricle: JACC: Cardiovascular Imaging Expert Panel Paper
Excessive trabeculation, often referred to as “noncompacted” myocardium, has been
described at all ages, from the fetus to the adult. Current evidence for myocardial …
described at all ages, from the fetus to the adult. Current evidence for myocardial …
Dilated cardiomyopathy: causes, mechanisms, and current and future treatment approaches
Dilated cardiomyopathy is conventionally defined as the presence of left ventricular or
biventricular dilatation or systolic dysfunction in the absence of abnormal loading conditions …
biventricular dilatation or systolic dysfunction in the absence of abnormal loading conditions …
Catheter Ablation or Antiarrhythmic Drugs for Ventricular Tachycardia
Background Patients with ventricular tachycardia and ischemic cardiomyopathy are at high
risk for adverse outcomes. Catheter ablation is commonly used when antiarrhythmic drugs …
risk for adverse outcomes. Catheter ablation is commonly used when antiarrhythmic drugs …
AIEgen‐Based Covalent Organic Frameworks for Preventing Malignant Ventricular Arrhythmias Via Local Hyperthermia Therapy
The engineering of aggregation‐induced emission luminogens (AIEgen) based covalent
organic frameworks (COFs), TDTA‐COF, BTDTA‐COF, and BTDBETA‐COF are reported, as …
organic frameworks (COFs), TDTA‐COF, BTDTA‐COF, and BTDBETA‐COF are reported, as …
Mislocalization of pathogenic RBM20 variants in dilated cardiomyopathy is caused by loss-of-interaction with Transportin-3
Severe forms of dilated cardiomyopathy (DCM) are associated with point mutations in the
alternative splicing regulator RBM20 that are frequently located in the arginine/serine-rich …
alternative splicing regulator RBM20 that are frequently located in the arginine/serine-rich …